[News] NHS England ends treatment break rule in bowel cancer

In an important change in policy, NHS England has permanently exempted the EGFR inhibitor therapies cetuximab and panitumumab in KRAS wild-type, metastatic colorectal cancer from its ban on unplanned treatment breaks. Until mid-June 2023, patients taking a treatment break of longer than 6 weeks for any reason risk the withdrawal of NHS funding for future treatment cycles.